Acute and long-term toxicity in patients undergoing induction chemotherapy followed by thermoradiotherapy for advanced cervical cancer

References

• Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65(2):87–108.
   PubMed Web of Science ®Google Scholar
• Gaffney DK, Erickson-Wittmann BA, Jhingran A, et al. ACR appropriateness criteria(R) on advanced cervical cancer expert panel on radiation Oncology-Gynecology. Int J Radiat Oncol Biol Phys. 2011;81(3):609–614.
   PubMed Web of Science ®Google Scholar
• Hellebust TP, Kirisits C, Berger D, et al. Recommendations from gynaecological (GYN) GEC-ESTRO working group: considerations and pitfalls in commissioning and applicator reconstruction in 3D image-based treatment planning of cervix cancer brachytherapy. Radiother Oncol. 2010;96(2):153–160.
   PubMed Web of Science ®Google Scholar
• Green J, Kirwan J, Tierney J, et al. Concomitant chemotherapy and radiation therapy for cancer of the uterine cervix. Cochrane Database Syst Rev. 2005;(3):CD002225.
   PubMed Web of Science ®Google Scholar
• Vale CL, Tierney JF, Davidson SE, et al. Substantial improvement in UK cervical cancer survival with chemoradiotherapy: results of a royal college of radiologists’ audit. Clin Oncol (R Coll Radiol). 2010;22(7):590–601.
   PubMed Web of Science ®Google Scholar
• Lutgens L, van der Zee J, Pijls-Johannesma M, et al. Combined use of hyperthermia and radiation therapy for treating locally advanced cervix carcinoma. Cochrane Database Syst Rev. 2010;(1):CD006377.
   Web of Science ®Google Scholar
• Sorensen HT, Mellemkjaer L, Olsen JH, et al. Prognosis of cancers associated with venous thromboembolism. N Engl J Med. 2000;343(25):1846–1850.
   PubMed Web of Science ®Google Scholar
• Fowkes FJ, Price JF, Fowkes FG. Incidence of diagnosed deep vein thrombosis in the general population: systematic review. Eur J Vasc Endovasc Surg. 2003;25(1):1–5.
   PubMed Web of Science ®Google Scholar
• Jacobson GM, Kamath RS, Smith BJ, et al. Thromboembolic events in patients treated with definitive chemotherapy and radiation therapy for invasive cervical cancer. Gynecol Oncol. 2005;96(2):470–474.
   PubMed Web of Science ®Google Scholar
• Heijkoop ST, Franckena M, Thomeer MG, et al. Neoadjuvant chemotherapy followed by radiotherapy and concurrent hyperthermia in patients with advanced-stage cervical cancer: a retrospective study. Int J Hyperthermia. 2012;28(6):554–561.
   PubMed Web of Science ®Google Scholar
• Heijkoop ST, Langerak TR, Quint S, et al. Clinical implementation of an online adaptive plan-of-the-day protocol for nonrigid motion management in locally advanced cervical cancer IMRT. Int J Radiat Oncol Biol Phys. 2014;90(3):673–679.
   PubMed Web of Science ®Google Scholar
• Kroesen M, Mulder HT, van Holthe JML, et al. Confirmation of thermal dose as a predictor of local control in cervical carcinoma patients treated with state-of-the-art radiation therapy and hyperthermia. Radiother Oncol. 2019;140:150–158.
   PubMed Web of Science ®Google Scholar
• Pötter R, Dimopoulos J, Georg P, et al. Clinical impact of MRI assisted dose volume adaptation and dose escalation in brachytherapy of locally advanced cervix cancer. Radiother Oncol. 2007;83(2):148–155.
   PubMed Web of Science ®Google Scholar
• Kitagawa R, Katsumata N, Shibata T, et al. Paclitaxel plus carboplatin versus paclitaxel plus cisplatin in metastatic or recurrent cervical cancer: the open-label randomized phase III trial JCOG0505. J Clin Oncol. 2015;33(19):2129–2135.
   PubMed Web of Science ®Google Scholar
• Lorusso D, Petrelli F, Coinu A, et al. A systematic review comparing cisplatin and carboplatin plus paclitaxel-based chemotherapy for recurrent or metastatic cervical cancer. Gynecol Oncol. 2014;133(1):117–123.
   PubMed Web of Science ®Google Scholar
• Latcha S, Jaimes EA, Patil S, et al. Long-term renal outcomes after cisplatin treatment. Clin J Am Soc Nephrol. 2016;11(7):1173–1179.
   PubMed Web of Science ®Google Scholar
• Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228–247.
   PubMed Web of Science ®Google Scholar
• Sauerbrei W, Royston P, Binder H. Selection of important variables and determination of functional form for continuous predictors in multivariable model building. Stat Med. 2007;26(30):5512–5528.
   PubMed Web of Science ®Google Scholar
• Steyerberg EW, Eijkemans MJC, Harrell FE, et al. Prognostic modelling with logistic regression analysis: a comparison of selection and estimation methods in small data sets. Stat Med. 2000;19(8):1059–1079.
   PubMed Web of Science ®Google Scholar
• Vittinghoff E, McCulloch CE. Relaxing the rule of ten events per variable in logistic and cox regression. Am J Epidemiol. 2007;165(6):710–718.
   PubMed Web of Science ®Google Scholar
• de Jongh FE, de Wit R, Verweij J, et al. Dose-dense cisplatin/paclitaxel. a well-tolerated and highly effective chemotherapeutic regimen in patients with advanced ovarian cancer. Eur J Cancer. 2002;38(15):2005–2013.
   PubMed Web of Science ®Google Scholar
• Torfs S, Cadron I, Amant F, et al. Evaluation of paclitaxel/carboplatin in a dose dense or weekly regimen in 66 patients with recurrent or primary metastatic cervical cancer. Eur J Cancer. 2012;48(9):1332–1340.
   PubMed Web of Science ®Google Scholar
• Gemma K, Stefano G, Ignace V, et al. Results from neoadjuvant chemotherapy followed by surgery compared to chemoradiation for stage Ib2-IIb cervical cancer, EORTC 55994. J Clin Oncol. 2019;37(15_suppl):5503.
   Web of Science ®Google Scholar
• Gupta S, Maheshwari A, Parab P, et al. Neoadjuvant chemotherapy followed by radical surgery versus concomitant chemotherapy and radiotherapy in patients with stage IB2, IIA, or IIB squamous cervical cancer: a randomized controlled trial. J Clin Oncol. 2018;36(16):1548–1555.
   PubMed Web of Science ®Google Scholar
• Roura E, Castellsagué X, Pawlita M, et al. Smoking as a major risk factor for cervical cancer and pre-cancer: results from the EPIC cohort. Int J Cancer. 2014;135(2):453–466.
   PubMed Web of Science ®Google Scholar
• Mizuno T, Ishikawa K, Sato W, et al. The risk factors of severe acute kidney injury induced by cisplatin. Oncology. 2013;85(6):364–369.
   PubMed Web of Science ®Google Scholar
• Stewart DJ, Dulberg CS, Mikhael NZ, et al. Association of cisplatin nephrotoxicity with patient characteristics and cisplatin administration methods. Cancer Chemother Pharmacol. 1997;40(4):293–308.
   PubMed Web of Science ®Google Scholar
• Astor BC, Hallan SI, Miller ER 3rd, et al. Glomerular filtration rate, albuminuria, and risk of cardiovascular and all-cause mortality in the US population. Am J Epidemiol. 2008;167(10):1226–1234.
   PubMed Web of Science ®Google Scholar
• Cohen A, Lim CS, Davies AH. Venous thromboembolism in gynecological malignancy. Int J Gynecol Cancer. 2017;27(9):1970–1978.
   PubMed Web of Science ®Google Scholar
• Seng S, Liu Z, Chiu SK, et al. Risk of venous thromboembolism in patients with cancer treated with cisplatin: a systematic review and meta-analysis. J Clin Oncol. 2012;30(35):4416–4426.
   PubMed Web of Science ®Google Scholar
• Proverbs-Singh T, Chiu SK, Liu Z, et al. Arterial thromboembolism in cancer patients treated with cisplatin: a systematic review and meta-analysis. J Natl Cancer Inst. 2012;104(23):1837–1840.
   PubMedGoogle Scholar
• Prandoni P, Piccioli A, Girolami A. Cancer and venous thromboembolism: an overview. Haematologica. 1999;84(5):437–445.
   PubMed Web of Science ®Google Scholar
• Soultati A, Mountzios G, Avgerinou C, et al. Endothelial vascular toxicity from chemotherapeutic agents: preclinical evidence and clinical implications. Cancer Treat Rev. 2012;38(5):473–483.
   PubMed Web of Science ®Google Scholar
• Monreal M, Falgá C, Valle R, et al. Venous thromboembolism in patients with renal insufficiency: findings from the RIETE registry. Am J Med. 2006;119(12):1073–1079.
   PubMed Web of Science ®Google Scholar
• Khorana AA, Francis CW, Culakova E, et al. Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy. J Thromb Haemost. 2007;5(3):632–634.
   PubMed Web of Science ®Google Scholar
• Agnelli G, Gussoni G, Bianchini C, et al. Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy: a randomised, placebo-controlled, double-blind study. Lancet Oncol. 2009;10(10):943–949.
   PubMed Web of Science ®Google Scholar
• Agnelli G, George DJ, Kakkar AK, et al. Semuloparin for thromboprophylaxis in patients receiving chemotherapy for cancer. N Engl J Med. 2012;366(7):601–609.
   PubMed Web of Science ®Google Scholar
• Liu M, Wang G, Li Y, et al. Efficacy and safety of thromboprophylaxis in cancer patients: a systematic review and meta-analysis. Ther Adv Med Oncol. 2020;12:1758835920907540.
   Web of Science ®Google Scholar
• Pötter R, Tanderup K, Schmid MP, et al. MRI-guided adaptive brachytherapy in locally advanced cervical cancer (EMBRACE-I): a multicentre prospective cohort study. Lancet Oncol. 2021;22(4):538–547.
   PubMed Web of Science ®Google Scholar
• Pergialiotis V, Bellos I, Thomakos N, et al. Survival outcomes of patients with cervical cancer and accompanying hydronephrosis: a systematic review of the literature. Oncol Rev. 2019;13(1):387.
   PubMed Web of Science ®Google Scholar
• Rose PG, Bundy BN, Watkins EB, et al. Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer. N Engl J Med. 1999;340(15):1144–1153.
   Google Scholar
• Franckena M, Stalpers LJ, Koper PC, et al. Long-term improvement in treatment outcome after radiotherapy and hyperthermia in locoregionally advanced cervix cancer: an update of the dutch deep hyperthermia trial. Int J Radiat Oncol Biol Phys. 2008;70(4):1176–1182.
   PubMed Web of Science ®Google Scholar
• Datta NR, Puric E, Klingbiel D, et al. Hyperthermia and radiation therapy in locoregional recurrent breast cancers: a systematic review and meta-analysis. Int J Radiat Oncol Biol Phys. 2016;94(5):1073–1087.
   PubMed Web of Science ®Google Scholar
• Mileshkin L, Moore KN, Barnes E, et al., editors. Adjuvant chemotherapy following chemoradiation as primary treatment for locally advanced cervical cancer compared to chemoradiation alone: the randomized phase III OUTBACK Trial (ANZGOG 0902, RTOG 1174, NRG 0274). 2021 ASCO Annual Meeting; 2021 Jun 4–8, Online Meeting. J Clin Oncol 39, 2021 (suppl 15; abstr LBA3). Available from: https://meetinglibrary.asco.org/record/196619/abstract.
   Google Scholar
• van den Tempel N, Horsman MR, Kanaar R. Improving efficacy of hyperthermia in oncology by exploiting biological mechanisms. Int J Hyperthermia. 2016;32(4):446–454.
   PubMed Web of Science ®Google Scholar